Parkinson Protein 2, E3 Ubiquitin Protein Ligase (Parkin) (PARK2) (Middle Region) Peptide
PARK2
Reactivity: Human
Host: Synthetic
BP, WB
-
- Target See all Parkin (PARK2) products
- Parkin (PARK2) (Parkinson Protein 2, E3 Ubiquitin Protein Ligase (Parkin) (PARK2))
- Protein Region
- Middle Region
- Origin
- Human
-
Source
- Synthetic
- Application
- Blocking Peptide (BP), Western Blotting (WB)
- Sequence
- GKELRNDWTV QNCDLDQQSI VHIVQRPWRK GQEMNATGGD DPRNAAGGCE
- Characteristics
- This is a synthetic peptide designed for use in combination with anti- PARK2 Antibody. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
-
-
- Application Notes
- Optimal working dilution should be determined by the investigator.
- Restrictions
- For Research Use only
-
- Format
- Lyophilized
- Reconstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
- Storage
- -20 °C
- Storage Comment
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
- Target
- Parkin (PARK2) (Parkinson Protein 2, E3 Ubiquitin Protein Ligase (Parkin) (PARK2))
- Background
-
The precise function of this gene is unknown, however, the encoded protein is a component of a multiprotein E3 ubiquitin ligase complex that mediates the targeting of substrate proteins for proteasomal degradation. Mutations in this gene are known to cause Parkinson disease and autosomal recessive juvenile Parkinson disease. Alternative splicing of this gene produces multiple transcript variants encoding distinct isoforms. Additional splice variants of this gene have been described but currently lack transcript support. [provided by RefSeq, Jul 2008]
Alias Symbols: PDJ, AR-JP, LPRS2, PARK2
Protein Size: 465 - Gene ID
- 5071
- NCBI Accession
- NM_004562, NP_004553
- UniProt
- O60260
-
You are here:
